Journal of Clinical Oncology, Vol 11, 360-368, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis [published erratum appears in J Clin Oncol 1994 Mar;12(3):643]

EE Vokes, MJ Ratain, R Mick, JM McEvilly, D Haraf, M Kozloff, V Hamasaki, RR Weichselbaum, WR Panje and B Wenig
Department of Medicine, University of Chicago Pritzker School of Medicine, IL.

PURPOSE: To increase the activity of cisplatin, fluorouracil (5-FU), and leucovorin (PFL) through further biochemical modulation and study the pharmacologic interaction of 5-FU and interferon alfa-2b (IFN). PATIENTS AND METHODS: Escalating doses of IFN (0.5 to 4.0 x 10(6) U/m2/d x 6) were added to cisplatin 100 mg/m2, continuous infusion 5-FU 800 or 640 mg/m2/d x 5, and leucovorin 100 mg orally every 4 hours. Forty-eight previously untreated patients with locoregionally advanced head and neck cancer received up to three cycles of PFL-IFN. RESULTS: Twenty-one patients were treated during a phase I cohort study. Dose- limiting mucositis was seen with 800 mg/m2/d of 5-FU and 0.5 x 10(6) U/m2/d of IFN. After decreasing the 5-FU dose to 640 mg/m2/d, the maximally tolerated dose (MTD) of IFN was 2.0 x 10(6) U/m2/d. Mucositis and myelosuppression were dose-limiting. Of 34 patients treated at this MTD, 56% (95% confidence interval, 39% to 73%) had a complete remission. There was no correlation between 5-FU clearance and IFN dose. Pharmacodynamic analyses at the MTD showed that older age, female sex, and higher 5-FU area under the time versus concentration curve (AUC) were associated with lower nadir counts and/or increased mucositis. Seven patients with diabetes mellitus had significantly increased myelosuppression, serum creatinine, hypocalcemia, higher 5-FU concentrations, and lower 5-FU clearance compared with nondiabetics. CONCLUSION: The recommended doses for PFL-IFN are 640 mg/m2/d for 5-FU and 2.0 x 10(6) U/m2/d for IFN. Sex, age, 5-FU AUC, and diabetes mellitus may have an impact on the pharmacodynamics of this regimen.

This article has been cited by other articles:

				T. Tanvetyanon and A. M Choudhury Hypocalcemia and Azotemia Associated with Zoledronic Acid and Interferon Alfa Ann. Pharmacother., March 1, 2004; 38(3): 418 - 421. [Abstract] [Full Text] [PDF]

				M. S. Kies, D. J. Haraf, F. Rosen, K. Stenson, M. List, B. Brockstein, T. Chung, B. B. Mittal, H. Pelzer, L. Portugal, et al. Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer J. Clin. Oncol., April 1, 2001; 19(7): 1961 - 1969. [Abstract] [Full Text] [PDF]

				K. M. Stenson, D. J. Haraf, H. Pelzer, W. Recant, M. S. Kies, R. R. Weichselbaum, and E. E. Vokes The Role of Cervical Lymphadenectomy After Aggressive Concomitant Chemoradiotherapy: The Feasibility of Selective Neck Dissection Arch Otolaryngol Head Neck Surg, August 1, 2000; 126(8): 950 - 956. [Abstract] [Full Text] [PDF]

				E. E. Vokes, M. S. Kies, D. J. Haraf, K. Stenson, M. List, R. Humerickhouse, M. E. Dolan, H. Pelzer, L. Sulzen, M. E. Witt, et al. Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1652 - 1661. [Abstract] [Full Text] [PDF]

				A. Rosen, E. E. Vokes, N. Scher, D. Haraf, R. R. Weichselbaum, and W. R. Panje Locoregionally Advanced Paranasal Sinus Carcinoma: Favorable Survival With Multimodality Therapy Arch Otolaryngol Head Neck Surg, July 1, 1993; 119(7): 743 - 746. [Abstract] [PDF]